The initiatives reflect the latest measures from federal agencies to reduce and ultimately replace animal testing in drug development and biomedical research....more
Recent developments include leadership changes, workforce reductions, and policy shifts at HHS and FDA, reshaping agency operations under President Trump’s administration....more
5/16/2025
/ Department of Health and Human Services (HHS) ,
Deregulation ,
Enforcement Priorities ,
Executive Orders ,
Food and Drug Administration (FDA) ,
Government Agencies ,
Life Sciences ,
Reduction of Force ,
Regulatory Agenda ,
Reorganizations ,
Rulemaking Process ,
Trump Administration
The final guidance describes FDA’s enforcement discretion policy for sharing scientific information on unapproved uses of approved products and suggests a safe harbor for sharing off-label information consistent with the...more
1/16/2025
/ Compliance ,
Data-Sharing ,
Enforcement ,
Final Guidance ,
Final Rules ,
Food and Drug Administration (FDA) ,
Life Sciences ,
Off-Label Use ,
Pharmaceutical Industry ,
Prescription Drugs ,
Regulatory Authority ,
Regulatory Requirements ,
Risk Management ,
Safe Harbors